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15-Year outcome after normal exercise 99mTc-
sestamibi myocardial perfusion imaging: What is
the duration of low risk after a normal scan?
Arend F. L. Schinkel, MD, PhD,a,b Henk J. Boiten, MS,a Jors N. van der Sijde, MS,a
Pauline R. Ruitinga, MD,a Eric J. G. Sijbrands, MD, PhD,b Roelf Valkema, MD,
PhD,c and Ron T. van Domburg, PhDa
Objective. The goal of this study was to evaluate the very long-term outcome after normal
exercise 99mTc-sestamibi myocardial perfusion single-photon emission computed tomography
(SPECT). Exercise 99mTc-sestamibi SPECT is widely used for risk stratification, but data on
very long-term outcome after a normal test are scarce.
Methods. A consecutive group of 233 patients (122 men, mean age 54 ± 12 years) with
known or suspected coronary artery disease (CAD) underwent exercise 99mTc-sestamibi SPECT
and had normal myocardial perfusion at exercise and at rest. Follow-up endpoints were all-
cause mortality, cardiac mortality, nonfatal myocardial infarction, and coronary revasculari-
zation. Predictors of outcome were identified by Cox proportional hazard regression models
using clinical and exercise testing variables.
Results. During a mean follow-up of 15.5 ± 4.9 years, 41 (18%) patients died, of which 13 were
cardiac deaths. A total of 18 (8%) patients had a nonfatal myocardial infarction, and 47 (20%) had
coronary revascularization. The annualized event rates for all-cause mortality, cardiac mortality,
cardiac mortality/nonfatal infarction, and major adverse cardiac events were, respectively, 1.1%,
0.3%, 0.7%, and 1.8%. Multivariate analysis demonstrated that the variables age, male gender,
diabetes, diastolic blood pressure at rest, rate pressure product at rest, peak exercise heart rate, and
ST segment changes were independent predictors of major adverse cardiac events.
Conclusion. Patients with suspected or known CAD and normal exercise 99mTc-sestamibi
myocardial perfusion SPECT have a favorable 15-year prognosis. Follow-up should be closer in
patients with known CAD, and/or having clinical and exercise parameters indicating higher risk
status. (J Nucl Cardiol 2012;19:901–6.)
Key Words: Coronary disease Æ prognosis Æ follow-up studies Æ radioisotopes
INTRODUCTION
Exercise 99mTc-sestamibi myocardial perfusion sin-
gle-photon emission computed tomography (SPECT)
provides clinically useful information for diagnosis and
risk stratification of patients with known or suspected
coronary artery disease (CAD). Accurate risk stratifi-
cation of these patients is required to optimize patient
management. A recent meta-analysis of the literature
demonstrated that normal myocardial perfusion SPECT
has a high negative predictive value for cardiac
events.1,2 Patients with normal myocardial perfusion
SPECT are considered at low risk of cardiac events,
the annualized event rate is generally \1% during the
first few years after testing. Accordingly, in these low-
risk patients, further (invasive) diagnostic and thera-
peutic strategies and associated medical care costs can
be avoided.1-3
However, over time, a significant change in risk
may occur after a normal myocardial perfusion SPECT.
The underlying clinical risk and history of CAD
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significantly influence the event rate after a normal
myocardial perfusion SPECT. Moreover, a temporal
component of risk has been identified, which may
increase the annualized cardiac event rate to 2%, even in
the presence of a normal myocardial perfusion SPECT.4
These observations have led to the perception that a
‘‘warranty period’’ exists after a normal myocardial
perfusion SPECT. In the currently available literature,
mean follow-up after myocardial perfusion SPECT was
approximately 3 years.1-3 Data of very long-term out-
come after normal myocardial perfusion SPECT are
lacking, and consequently, the duration of the low-risk
status after a normal test is not clear. This creates
uncertainties in patient management recommendations.
The goals of the current study were as follows: (1) To
assess very long-term outcome after normal myocardial
perfusion SPECT. (2) To define a low-risk period after
normal myocardial perfusion SPECT. (3) To identify
predictors of increased risk.
METHODS
Study Design
The study population consisted of 242 consecutive
patients with known or suspected CAD who underwent
exercise 99mTc-sestamibi myocardial perfusion SPECT and
had normal myocardial perfusion at exercise and at stress. The
majority of the study population has been described in a
previous study from our center.5 The local medical ethics
committee approved the protocol, and all the patients gave
informed consent. A structured interview and clinical history
were obtained, including assessment of cardiac risk factors,
and the symptoms before the exercise test.
Exercise Testing Protocol
All the patients performed a symptom-limited upright
bicycle ergometry test with stepwise increment of 20 W every
minute. Cuff blood pressure measurement and standard 12-lead
surface electrocardiograms were obtained at rest and every
minute during exercise, until the end of the recovery phase.
The electrocardiograms were digitally stored and analyzed by
an experienced observer. Test endpoints included the follow-
ing: severe angina, decrease in systolic blood pressure fall
[40 mm Hg, blood pressure[240/120 mm Hg, or significant
cardiac arrhythmia. An ischemic response was defined as
C1 mm horizontal or downsloping ST-segment depression at
80 ms after the J point.
Myocardial Perfusion SPECT
Approximately 1 minute before the termination of the
exercise test, an intravenous dose of 370 MBq of 99mTc-
sestamibi was administered as previously described.5 For
resting studies, 370 MBq of the same tracer was administered
at least 24 h after the exercise test. Image acquisition was
performed using a SPECT camera system (Orbiter camera;
Siemens, Iselin, NJ; or Picker Prism 3000XP camera; Picker,
Cleveland, OH). Thirty-two projections were obtained, from
the left posterior oblique to the right anterior oblique over
180. The semiquantitative interpretation of the scan was
performed by visual analysis assisted by the circumferential
profiles analysis. Stress and rest tomographic views were
reviewed side-by-side by two experienced observers who were
unaware of the patients’ clinical data. In case of disagreement,
a majority decision was achieved by a third observer. A normal
study was defined as the absence of perfusion abnormalities.
Patient Follow-Up
Follow-up data were collected in the year 2011 and were
completed in respect of 233 patients (96%). Outcome data
were obtained by evaluation of hospital records, contacting the
patient’s general practitioner, and/or review of civil registries.
The date of the last review or consultation was used to
calculate follow-up time. Endpoints were all-cause mortality,
cardiac death, nonfatal myocardial infarction, and coronary
revascularization. Nonfatal myocardial infarction was defined
as new symptoms of ischemia, and/or ECG changes indicative
of new ischemia, and/or imaging evidence of myocardial
infarction, accompanied by detection of a rise and fall of
cardiac biomarkers.6 Major adverse cardiac events (MACE)
were defined as the occurrence of cardiac death, nonfatal
myocardial infarction, or revascularization.
Statistical Analysis
Values were expressed as mean ± SD or number, and
compared using the Student’s t test or chi-squared test.
Univariate and multivariate Cox proportional hazard regres-
sion models (SPSS statistical software version 15.0, SPSS,
Chicago, IL) were used to identify independent predictors of
outcome.7 Variables were selected in a stepwise forward
selection manner with entry and retention set at a significance
level of .05. The risk of a variable was expressed as a hazard
ratio with a corresponding 95% confidence interval. The
probability of survival was calculated using the Kaplan-Meier
method, and survival curves were compared using the log-rank
test. P value \.05 was considered statistically significant.
RESULTS
Clinical Characteristics
Clinical characteristics of the 233 patients are sum-
marized in Table 1. A total of 222 (95%) patients had an
interpretable ECG at baseline. There were no major side
effects or complications as result of the test. There was a
significant increase in heart rate (78 ± 15 to 147 ± 24
beats/minute, P \ .001), and systolic blood pressure
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(138 ± 22 to 188 ± 25 mm Hg, P \ .001 from rest to peak
exercise. The mean workload was 143 ± 43 W, corre-
sponding with an exercise duration of 7 minutes. The target
heart rate (85% of the maximal predicted heart rate) was
reached in 173 patients (74%). Exercise-induced angina
occurred in 29 (12%) patients, and 19 (8%) had ST segment
depression during the exercise test.
Outcome
Kaplan-Meier survival curves and cumulative event
rate are presented in Figures 1, 2, 3, 4, and 5. During a
mean follow-up of 15.5 ± 4.9 years, 41 (18%) patients
died, of which 13 were cardiac deaths. A total of 18
(8%) patients had a nonfatal myocardial infarction.
Coronary revascularization procedures were performed
in 47 patients (20%). Seventeen patients (7%) under-
went coronary artery bypass surgery, and 30 (13%)
underwent percutaneous coronary intervention. The
annualized event rates for all-cause mortality, cardiac
mortality, cardiac mortality/nonfatal infarction, and
major adverse cardiac events were respectively 1.1%,
0.3%, 0.7%, and 1.8%. All-cause mortality was signif-
icantly higher in patients with known CAD (Figure 5).
Risk Stratification
Univariate analysis demonstrated that age, diabetes
mellitus, diastolic blood pressure at rest, and heart rate
during exercise was predictors of all-cause mortality
(Table 2). Diastolic blood pressures at rest and peak
exercise heart rate were predictors of cardiac mortality.
Beta-blocker use, and peak exercise heart rate were
predictors of cardiac mortality/nonfatal infarction. Age,
male gender, diastolic blood pressure at rest and peak
exercise heart rate were predictors of major adverse
cardiac events.
Multivariate models demonstrated that age, male
gender, diabetes, heart rate at rest and peak exercise
heart rate were independent predictors of all-cause
Table 1. Patient characteristics
Age (years) 54 ± 12
Men 122 (52%)
Height (cm) 170 ± 10
Weight (kg) 74 ± 13
Hypertension 78 (33%)
Smoking 61 (26%)
Hypercholesterolemia 63 (27%)
Diabetes mellitus 16 (7%)
ACE-inhibitor 29 (12%)
Beta-blocker 78 (33%)
Known coronary artery disease 57 (24%)
Prior coronary revascularization 55 (24%)
Prior myocardial infarction 19 (8%)
Typical angina 58 (25%)
Atypical angina 120 (52%)
Nonspecific symptoms 14 (6%)
No symptoms 41 (18%)
Figure 1. Kaplan-Meier event-free survival for the endpoint
of all-cause mortality in patients with normal exercise 99mTc-
sestamibi myocardial perfusion SPECT.
Figure 2. Kaplan-Meier event-free survival for the endpoint
of cardiac mortality in patients with normal exercise 99mTc-
sestamibi myocardial perfusion SPECT.
Figure 3. Kaplan-Meier event-free survival for the endpoint
of cardiac mortality and nonfatal myocardial infarction in
patients with normal exercise 99mTc-sestamibi myocardial
perfusion SPECT.
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mortality (Table 3). Heart rate at rest and peak exercise
heart rate were predictors of cardiac mortality (Table 4).
Male gender, diabetes, and peak exercise heart rate were
predictors of cardiac mortality/nonfatal infarction
(Table 5). Age, male gender, diabetes, diastolic blood
pressure at rest, rate pressure product at rest, peak
exercise heart rate, and ST segment changes were
independent predictors of major adverse cardiac events
(Table 6).
DISCUSSION
In this study, very long-term outcome after normal
exercise 99mTc-sestamibi myocardial perfusion SPECT
was assessed in respect of 233 patients with known or
suspected CAD. The 15.5 ± 4.9-year follow-up demon-
strated that the overall outcome of these patients was
favorable. Annualized event rates were relatively low
during the entire follow-up period. Particularly, in the
first 5 years after normal exercise 99mTc-sestamibi
myocardial perfusion SPECT, annualized event rates
were very low. Predictors of increased risk were
identified by multivariate analyses of clinical and
exercise test data. Clinical predictors of adverse out-
come were age, male gender, and diabetes. Exercise
testing variables associated with an increased risk were
heart rate at rest, peak exercise heart rate, diastolic blood
pressure at rest, rate pressure product at rest, and ST
segment changes.
Currently, there are no studies providing very long-
term outcome data, and consequently the duration of the
low-risk status after a normal test is not clear.1-4 Several
previous studies have reported on the medium-term
prognosis after a normal myocardial perfusion SPECT.
In these previous studies, the number of included
patients ranged from 88 to 273, and mean follow-up
ranged from 10 months to 7.4 years.1-3 In the available
literature, mean follow-up after myocardial perfusion
SPECT was approximately 3 years.1-3 The previous
studies have demonstrated that the medium-term prog-
nosis of patients with suspected or known CAD and
normal myocardial perfusion SPECT is favorable.
Moreover, several large observational series have stud-
ied medium-term prognosis in patients with normal or
low-risk thallium-201, 99mTc-sestamibi, and 99mTc-te-
trofosmin. Meta-analyses of these series revealed that
the annualized cardiac mortality rate was approximately
0.5%.1,2 The Dutch Heart Foundation data8 indicate that
all-cause mortality in men aged 55-64 years, during the
period 1986-1998 was (min-max) 2808-3175, and car-
diac mortality was 206-422/100.000. In women aged
55-64 years, in the period 1985-1996, all-cause mortality
was (min-max) 476-771, and cardiac mortality was 64.9-
106/100.000. Hence, the event rates in the general
population appear to be lower than in the study
population. The study patients were referred to exercise
myocardial perfusion SPECT by their treating physi-
cians, and the risk profile of the patients was different
from that of the general population. In the present study
with 15-year follow-up annualized cardiac mortality rate
was 0.3% using exercise 99mTc-sestamibi myocardial
perfusion SPECT.
The present study demonstrates that patients with a
normal exercise 99mTc-sestamibi myocardial perfusion
SPECT have a favorable prognosis even at 15-year
follow-up. In these patients a watchful waiting approach
to care is justified, and additional diagnostic strategies
including invasive coronary angiography can be avoi-
ded. Previous studies have shown that this type of
management strategy may be both clinically effective
and cost-effective.9,10 Clearly, clinical judgment
remains important in deciding patient management
decisions, also in patients with a normal exercise
99mTc-sestamibi myocardial perfusion SPECT. The
duration of the low-risk status depends on several
factors that influence the natural progression of
Figure 4. Kaplan-Meier event-free survival for the endpoint
of major adverse cardiac events in patients with normal
exercise 99mTc-sestamibi myocardial perfusion SPECT.
Figure 5. Kaplan-Meier event-free survival for the endpoint
of all-cause mortality in patients with normal exercise 99mTc-
sestamibi myocardial perfusion SPECT, with or without a
history of CAD.
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(subclinical) CAD. The present study demonstrates that
several clinical and exercise test parameters can be used
to identify patients at increased risk for adverse out-
come. Prognosis was worse in patients with a history of
CAD. Additionally multivariate analysis demonstrated
that several clinical and exercise testing parameters
influence very long-term outcome. Therefore, follow-up
should be closer in patients with known CAD, and/or
clinical and exercise parameters indicating higher risk
status. Repeated testing should be considered in patients
with a change in symptoms or worsening clinical status.
Table 2. Univariate predictors of outcome
All-cause
mortality
Cardiac
mortality
Cardiac mortality/
nonfatal infarction
Major adverse
cardiac events
Clinical features
Age[70 years 7.46 (2.84–19.51) 2.52 (0.51–12.56) 1.39 (0.38–5.10) 3.59 (1.37–9.38)
Male gender 1.53 (0.77–3.05) 2.53 (0.65–9.78) 1.96 (0.84–4.57) 2.44 (1.41–4.24)
Hypertension 0.79 (0.38–1.65) 0.43 (0.09–2.03) 1.43 (0.63–3.24) 1.43 (0.82–2.49)
Smoking 0.76 (0.34–1.69) 1.06 (0.27–4.13) 0.78 (0.30–2.05) 0.65 (0.34–1.21)
Hypercholesterolemia 0.60 (0.26–1.39) 0.26 (0.03–2.06) 1.16 (0.48–2.79) 1.19 (0.66–2.15)
Diabetes mellitus 3.12 (1.07–9.14) 1.38 (0.17–11.52) 2.81 (0.84–9.44) 2.35 (0.84–6.57)
ACE–inhibitor 1.97 (0.81–4.84) 0.69 (0.09–5.62) 0.53 (0.12–2.37) 1.25 (0.57–2.76)
Beta-blocker 0.91 (0.44–1.87) 1.70 (0.50–5.76) 2.39 (1.06–5.38) 1.62 (0.93–2.83)
Prior myocardial
infarction
1.77 (0.60–5.21) 1.13 (0.14–9.37) 2.21 (0.68–7.24) 2.57 (0.99–6.66)
Stress test results
Heart rate at rest 0.99 (0.89–1.18) 0.92 (0.61–1.40) 0.84 (0.64–1.11) 0.91 (0.79–1.04)
Peak exercise
heart rate
0.80 (0.71–0.90) 0.60 (0.46–0.86) 0.72 (0.60–0.86) 0.82 (0.75–0.90)
Diastolic blood
pressure rest
0.75 (0.58–0.97) 0.55 (0.31–0.98) 0.70 (0.46–1.05) 0.77 (0.63–0.95)
Rate pressure
product at rest
1.03 (0.93–1.14) 0.96 (0.75–1.22) 0.94 (0.80–1.10) 0.97 (0.90–1.05)
Typical angina 0.72 (0.24–2.20) 0.69 (0.09–5.62) 1.26 (0.40–3.94) 2.02 (0.92–4.43)
ST segment changes 0.53 (0.12–2.38) 0.00 (0.00–4.18) 0.89 (0.19–4.08) 1.28 (0.49–3.31)
Values are expressed as Cox proportional hazard ratio and 95% confidence interval.
Table 3. Multivariate predictors of all-cause
mortality
HR (95% CI) P value
Age* 1.06 (1.04–1.09) \.001
Male gender 2.70 (1.45–5.03) .002
Diabetes 3.06 (1.22–7.65) .02
Heart rate at rest 1.30 (1.07–1.58) .01
Peak exercise heart rate 0.80 (0.69–0.92) .03
Values are expressed as Cox proportional hazard ratio and
95% confidence interval.
* Per 1 unit increment.
Table 4. Multivariate predictors of cardiac
mortality
HR (95% CI) P value
Heart rate at rest 1.73 (1.02–2.94) .04
Peak exercise heart rate 0.50 (0.35–0.69) \.001
Values are expressed as Cox proportional hazard ratio and
95% confidence interval.
Table 5. Multivariate predictors of cardiac
mortality/nonfatal myocardial infarction
HR (95% CI) P value
Male gender 2.61 (1.11–6.14) .03
Diabetes 6.93 (2.18–22.04) .01
Peak exercise heart rate 0.70 (0.58–0.84) \.001
Values are expressed as Cox proportional hazard ratio and
95% confidence interval.
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STUDY LIMITATIONS
This study has some limitations. The study popu-
lation and the number of adverse events were relatively
small. Information on changes in medical therapy during
follow-up was not available. During the period when the
SPECT studies were performed, electrocardiogram
gated acquisition was not routinely performed in our
laboratory. Gated SPECT provides information on
regional and global left ventricular function, which is
an important predictor of long-term prognosis. Future
studies are needed to clarify the value of gated SPECT
for the assessment of very long-term prognosis in
patients with normal myocardial perfusion. Finally, in
the present study attenuation correction was not applied.
Recent data indicate that attenuation correction may
further improve diagnostic accuracy of myocardial
perfusion SPECT.11,12
CONCLUSION
Patients with suspected or known CAD and normal
exercise 99mTc-sestamibi myocardial perfusion SPECT
have a favorable 15-year prognosis. Prognosis is partic-
ularly favorable during the initial 5 years after testing.
Follow-up should be closer after this initial 5-year
period and in patients with known CAD, and/or having
clinical and exercise parameters indicating higher risk
status.
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